Sumitomo Mitsui Trust Group Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,091,193 shares of the biopharmaceutical company's stock after purchasing an additional 57,133 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.25% of Gilead Sciences worth $346,368,000 at the end of the most recent quarter.
A number of other large investors have also recently bought and sold shares of GILD. Annis Gardner Whiting Capital Advisors LLC grew its holdings in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after buying an additional 216 shares during the last quarter. Whipplewood Advisors LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $35,000. Investment Research & Advisory Group Inc. lifted its position in Gilead Sciences by 33.3% during the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after acquiring an additional 100 shares during the period. Synergy Investment Management LLC acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $40,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 83.67% of the company's stock.
Insiders Place Their Bets
In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now directly owns 121,152 shares of the company's stock, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock valued at $5,236,245 in the last ninety days. Insiders own 0.27% of the company's stock.
Wall Street Analyst Weigh In
GILD has been the subject of a number of recent research reports. Oppenheimer decreased their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Finally, Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.
Check Out Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Price Performance
NASDAQ:GILD traded up $3.05 during mid-day trading on Friday, hitting $110.67. 19,541,254 shares of the company's stock traded hands, compared to its average volume of 7,682,147. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm's 50 day simple moving average is $106.39 and its 200 day simple moving average is $103.35. Gilead Sciences, Inc. has a 1 year low of $66.01 and a 1 year high of $119.96. The company has a market cap of $137.67 billion, a PE ratio of 14.30, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the firm posted ($1.32) EPS. The firm's revenue for the quarter was down .3% on a year-over-year basis. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. The ex-dividend date was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.86%. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
